Insider Sale Under 10b5-1 Plan: APGE CMO Disposes 2,725 Shares

Rhea-AI Filing Summary

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported a sale of 2,725 shares of Apogee common stock on 08/06/2025 at a reported price of $37.78 per share. The transaction is recorded on a Form 4 and was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024, a plan described in the filing as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The filing shows that following the reported sale Mr. Dambkowski beneficially owned 236,273 shares, held directly. No derivative transactions are reported on this Form 4 and the document is limited to the single non-derivative sale and the related ownership position.

Positive

• Transaction executed under a Rule 10b5-1 trading plan, showing the sale was part of a pre-established plan adopted on August 21, 2024.
• Substantial remaining ownership is reported: 236,273 shares beneficially owned following the transaction, held directly.

Negative

• Insider disposition reported: the Chief Medical Officer sold 2,725 shares on 08/06/2025 at $37.78 per share.

Insights

Securities Analyst

TL;DR CMO sold 2,725 shares under a pre-established 10b5-1 plan; ownership remains at 236,273 shares, a routine disclosure.

The Form 4 documents a single non-derivative sale of 2,725 shares at $37.78 executed under a Rule 10b5-1 plan adopted on August 21, 2024. Because the trade was carried out pursuant to a pre-existing plan, it reduces the likelihood that this sale reflects new, material company information. The filing also reports a direct beneficial ownership of 236,273 shares after the transaction, which retains an explicit ownership stake by the reporting officer. Impact to investors is informational; no derivatives or additional transactions were disclosed.

Corporate Governance Expert

TL;DR Insider sale executed under a documented 10b5-1 plan; disclosure aligns with standard governance practice and enhances transparency.

The Form 4 specifies that the sale was made pursuant to a Rule 10b5-1 trading plan, which the filing states was adopted on August 21, 2024. Use of a documented trading plan and the timely Form 4 disclosure are consistent with accepted governance and insider-trading compliance practices. The report notes only a single non-derivative disposition and confirms direct beneficial ownership of 236,273 shares after the sale. From a governance perspective, the filing provides clear, itemized disclosure of the transaction and remaining ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		S(1)		2,725	D	$37.78	236,273	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Apogee (APGE) insider Carl Dambkowski report?

The filing reports a sale of 2,725 shares of Apogee common stock on 08/06/2025 at $37.78 per share.

Was the sale by the APGE CMO part of a 10b5-1 plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

How many Apogee shares does the reporting person own after the transaction?

The Form 4 shows the reporting person beneficially owned 236,273 shares following the reported sale.

Did the Form 4 report any derivative transactions for APGE?

No. The Form 4 contains only a non-derivative sale and explicitly shows no derivative transactions reported.

What is the reporting person's role at Apogee?

The reporting person, Carl Dambkowski, is identified as the company's Chief Medical Officer.

Who signed the Form 4 filing for this transaction?

The filing is signed by an attorney-in-fact, Matthew Batters, on behalf of Carl Dambkowski.